Efficacy and Safety of Sacral Neuromodulation by Converting Constant Frequency Stimulation Into Variable Frequency Stimulation in Patients With Detrusor Overactivity and Impaired Contractility: A Single-Center Prospective Study

• Published in: Neuromodulation (Malden, Mass.) Vol. 26; no. 8; pp. 1836 - 1844
• Main Authors: Zhu, Wen, Shan, Shuaishuai, Zhang, Guoxian, Zhang, Qinyong, Zhang, Jing, Che, Yingyu, Wen, Jianguo, Wang, Qingwei
• Format: Journal Article
• Language: English
• Published: United States 01.12.2023
• Subjects: Electric Stimulation Therapy - adverse effects; Electric Stimulation Therapy - methods; Humans; Prospective Studies; Quality of Life; Treatment Outcome; Urinary Bladder, Overactive - therapy; Urination; Urodynamics; Detrusor overactivity with impaired contractility; overactive bladder; sacral neuromodulation; dysuria; variable frequency stimulation
• ISSN: 1094-7159; 1525-1403
• DOI: 10.1016/j.neurom.2022.07.002

In patients with detrusor overactivity with impaired contractility (DOIC), it is difficult to relieve abnormal lower urinary tract symptoms during both storage and voiding using sacral neuromodulation (SNM) with constant frequency stimulation (CFS). We sought to evaluate the efficacy and safety of SNM using variable frequency stimulation (VFS) in patients with DOIC by comparing it with outcomes of SNM with CFS. Between September 2020 and May 2021, we prospectively enrolled 20 patients with DOIC, confirmed on urodynamic examination, and administered SNM with VFS. The patients were followed up and required to maintain voiding diaries and record scale scores of overactive bladder symptoms, psychology and quality of life, uroflowmetry, ultrasonic postvoid residual urine, and adverse events at baseline and during the CFS and VFS phases. The average testing phase was 26.3 ± 4.1 days. Compared with baseline values, overactive bladder symptom, psychologic health questionnaire, and quality of life scores, in addition to voiding frequency, urgency incontinence frequency, daily catheterization volume of voiding diary, and ultrasonic postvoid residual (PVR) decreased significantly during both the CFS and VFS phases (p < 0.05). The average voided volume, functional bladder capacity, and maximum urine flow rate significantly increased during the CFS and VFS phases (p < 0.05). In the VFS phase, voiding frequency, urgency incontinence frequency, daily catheterization volume of voiding diary, and ultrasonic PVR further decreased (p < 0.05), whereas functional bladder capacity, maximum urine flow rate, quality of life score, overactive bladder symptom score, and psychologic health questionnaire score further improved compared with results obtained in the CFS phase (p < 0.05). In the VFS phase, the success rate of further improvement of symptoms was 85.0%, and no new complications were noted. SNM that converts CFS into VFS may be an effective treatment option for patients with DOIC, exhibiting no increase in adverse events.